<?xml version='1.0' encoding='utf-8'?>
<document id="28800141"><sentence text="Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis."><entity charOffset="76-84" id="DDI-PubMed.28800141.s1.e0" text="Ixazomib" /></sentence><sentence text="At clinically relevant ixazomib concentrations, in vitro studies demonstrated that no specific cytochrome P450 (CYP) enzyme predominantly contributes to ixazomib metabolism"><entity charOffset="23-31" id="DDI-PubMed.28800141.s2.e0" text="ixazomib" /><entity charOffset="153-161" id="DDI-PubMed.28800141.s2.e1" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.28800141.s2.e0" e2="DDI-PubMed.28800141.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28800141.s2.e0" e2="DDI-PubMed.28800141.s2.e1" /></sentence><sentence text=" However, at higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms, with the estimated relative contribution being highest for CYP3A at 42%"><entity charOffset="50-58" id="DDI-PubMed.28800141.s3.e0" text="ixazomib" /></sentence><sentence text=" This multiarm phase 1 study (Clinicaltrials" /><sentence text="gov identifier: NCT01454076) investigated the effect of the strong CYP3A inhibitors ketoconazole and clarithromycin and the strong CYP3A inducer rifampin on the pharmacokinetics of ixazomib"><entity charOffset="84-96" id="DDI-PubMed.28800141.s5.e0" text="ketoconazole" /><entity charOffset="101-115" id="DDI-PubMed.28800141.s5.e1" text="clarithromycin" /><entity charOffset="145-153" id="DDI-PubMed.28800141.s5.e2" text="rifampin" /><entity charOffset="181-189" id="DDI-PubMed.28800141.s5.e3" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e0" e2="DDI-PubMed.28800141.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e0" e2="DDI-PubMed.28800141.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e0" e2="DDI-PubMed.28800141.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e0" e2="DDI-PubMed.28800141.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e1" e2="DDI-PubMed.28800141.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e1" e2="DDI-PubMed.28800141.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e1" e2="DDI-PubMed.28800141.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e2" e2="DDI-PubMed.28800141.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28800141.s5.e2" e2="DDI-PubMed.28800141.s5.e3" /></sentence><sentence text=" Eighty-eight patients were enrolled across the 3 drug-drug interaction studies; the ixazomib toxicity profile was consistent with previous studies"><entity charOffset="85-93" id="DDI-PubMed.28800141.s6.e0" text="ixazomib" /></sentence><sentence text=" Ketoconazole and clarithromycin had no clinically meaningful effects on the pharmacokinetics of ixazomib"><entity charOffset="1-13" id="DDI-PubMed.28800141.s7.e0" text="Ketoconazole" /><entity charOffset="18-32" id="DDI-PubMed.28800141.s7.e1" text="clarithromycin" /><entity charOffset="97-105" id="DDI-PubMed.28800141.s7.e2" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.28800141.s7.e0" e2="DDI-PubMed.28800141.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28800141.s7.e0" e2="DDI-PubMed.28800141.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28800141.s7.e0" e2="DDI-PubMed.28800141.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28800141.s7.e1" e2="DDI-PubMed.28800141.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28800141.s7.e1" e2="DDI-PubMed.28800141.s7.e2" /></sentence><sentence text=" The geometric least-squares mean area under the plasma concentration-time curve from 0 to 264 hours postdose ratio (90%CI) with vs without ketoconazole coadministration was 1"><entity charOffset="140-152" id="DDI-PubMed.28800141.s8.e0" text="ketoconazole" /></sentence><sentence text="09 (0" /><sentence text="91-1" /><sentence text="31) and was 1" /><sentence text="11 (0" /><sentence text="86-1" /><sentence text="43) with vs without clarithromycin coadministration"><entity charOffset="20-34" id="DDI-PubMed.28800141.s14.e0" text="clarithromycin" /></sentence><sentence text=" Reduced plasma exposures of ixazomib were observed following coadministration with rifampin"><entity charOffset="29-37" id="DDI-PubMed.28800141.s15.e0" text="ixazomib" /><entity charOffset="84-92" id="DDI-PubMed.28800141.s15.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28800141.s15.e0" e2="DDI-PubMed.28800141.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28800141.s15.e0" e2="DDI-PubMed.28800141.s15.e1" /></sentence><sentence text=" Ixazomib area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration was reduced by 74% (geometric least-squares mean ratio of 0"><entity charOffset="1-9" id="DDI-PubMed.28800141.s16.e0" text="Ixazomib" /></sentence><sentence text="26 [90%CI 0" /><sentence text="18-0" /><sentence text="37]), and maximum observed plasma concentration was reduced by 54% (geometric least-squares mean ratio of 0" /><sentence text="46 [90%CI 0" /><sentence text="29-0" /><sentence text="73]) in the presence of rifampin"><entity charOffset="24-32" id="DDI-PubMed.28800141.s22.e0" text="rifampin" /></sentence><sentence text=" The clinical drug-drug interaction study results were reconciled well by a physiologically based pharmacokinetic model that incorporated a minor contribution of CYP3A to overall ixazomib clearance and quantitatively considered the strength of induction of CYP3A and intestinal P-glycoprotein by rifampin"><entity charOffset="179-187" id="DDI-PubMed.28800141.s23.e0" text="ixazomib" /><entity charOffset="296-304" id="DDI-PubMed.28800141.s23.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.28800141.s23.e0" e2="DDI-PubMed.28800141.s23.e0" /><pair ddi="false" e1="DDI-PubMed.28800141.s23.e0" e2="DDI-PubMed.28800141.s23.e1" /></sentence><sentence text=" On the basis of these study results, the ixazomib prescribing information recommends that patients should avoid concomitant administration of strong CYP3A inducers with ixazomib"><entity charOffset="42-50" id="DDI-PubMed.28800141.s24.e0" text="ixazomib" /><entity charOffset="170-178" id="DDI-PubMed.28800141.s24.e1" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.28800141.s24.e0" e2="DDI-PubMed.28800141.s24.e0" /><pair ddi="false" e1="DDI-PubMed.28800141.s24.e0" e2="DDI-PubMed.28800141.s24.e1" /></sentence><sentence text="" /></document>